"Start Early": Oxperial Biohealth's Journey Collecting Human Evidence

When Oxperial first came to Alethios, their goal was clear: detect signal.

They had already been hearing consistent, encouraging feedback from individual users — reports of improved energy, resilience, and overall wellbeing. But anecdotes, no matter how positive, weren’t enough. They wanted to know: were these trends measurable? Could they be identified clearly and evaluated in a structured, scientific way?

As a young company pioneering “daylight active” herbal nutrition, they weren’t looking to run a pharma-scale trial. What they wanted was to understand whether their formulation was creating meaningful biological impact in real humans — and to do so with more rigor than is typically accessible to an early-stage startup.

What they weren’t sure of was how much rigor they could realistically accomplish.

Through the Alethios Early-Stage Program, that question quickly shifted from What’s possible? to How fast can we execute?

Raising the Bar on Early-Stage Rigor

From the beginning, Oxperial was clear about their philosophy:

“Human evidence is foundational. In health, consumers don’t just buy ingredients — they buy belief and confidence. And belief must be earned through building evidence.”

They knew preclinical science could explain mechanism. But they wanted to understand performance in real physiology and daily life.

For many early-stage supplement companies, that ambition is constrained by cost and infrastructure. Robust endpoints — wearable-derived physiological data and objective biomarkers — often feel financially and operationally out of reach.

Through discounted licensing and turnkey integration within the Alethios network, Oxperial was able to incorporate:

• Continuous wearable device data
• Structured participant tracking
• Objective inflammation marker collection

What once seemed untenable became achievable — without building heavy site infrastructure or exhausting early capital.

And critically, they were able to do it in a way that reflected how their products are actually used.

“The flexibility has been critical. Being able to run a structured, real-world human study without heavy site infrastructure allowed us to move faster, stay capital-efficient, and still maintain methodological integrity. From our point of view, for nutrition and wellness products, real-world human data is often more relevant than tightly controlled clinical environments.”

Why Alethios

For Oxperial, partnership mattered just as much as protocol.

“Alethios felt aligned from the beginning. They understand startups: the pace, constraints, and need for practicality. They’re incredibly responsive, collaborative, and genuinely care about enabling credible science in emerging health companies.”

That alignment showed up not just in study design, but in execution.

“Their ethos around accessible, well-designed human studies that are easier for the participants and companies resonated strongly with us.”

The Early-Stage Program was built to make rigorous human research feasible — not overwhelming — for growing companies. For Oxperial, that philosophy translated directly into momentum.

Navigating a First IRB Submission

This was Oxperial’s first human study.

For many founders, the regulatory pathway alone can feel intimidating. IRB submissions, study documentation, protocol language, consent structures — these are often unfamiliar processes for early-stage teams.

As part of the Early-Stage Program, Alethios worked closely with Oxperial to guide protocol development and support their IRB submission from draft to approval. The goal was not just compliance, but clarity — ensuring the study design aligned with long-term claims strategy and validation goals.

As Oxperial shared:

“As an early-stage company, you’re balancing speed, cost, scientific rigour, and operational reality all at once. Most clinical pathways are slower, expensive, and infrastructure-heavy, which can be difficult before large funding rounds.”

With the right structure and support, they were able to move forward confidently — knowing their first study met appropriate ethical and methodological standards.

Fully Enrolled — Ahead of Schedule

Once enrollment opened, momentum followed.

Oxperial reached full enrollment a month ahead of schedule.

For a startup balancing product development, fundraising, and operational growth, this acceleration mattered. It reduced uncertainty, preserved focus, and reinforced demand for evidence-backed herbal innovation.

The study officially concluded last week. Data collection is complete.

From Data to Insight

Analysis is now underway through one of Alethios’ in-network principal investigators — part of the program’s turnkey model that allows startups to move seamlessly from protocol to interpretation.

For Oxperial, this next phase bridges science and strategy.

“Human evidence bridges three things: scientific credibility, regulatory trust, and consumer confidence.”

The findings will inform claims development, investor conversations, and long-term positioning. In a supplement landscape often crowded with unvalidated products, human data shifts the narrative from “another product” to “validated technology.”

Building Without Waiting

Oxperial’s advice to other early-stage founders reflects their journey:

“Start early, and you don’t need a pharma-scale trial to begin generating human evidence. Well-designed, focused studies can already create scientific credibility and strategic clarity. Also, work with partners who understand early-stage realities.”

They came to Alethios seeking signal — unsure how much rigor was feasible at their stage.

They leave their first study fully enrolled ahead of schedule, with wearable and biomarker data in hand, and analysis underway through an experienced in-network PI.

For early-stage health founders considering their first study: you don’t have to wait. If you’re ready to move from testimonials to structured human evidence, the Alethios Early-Stage Program was built for exactly that step.

Read the full interview here.

‍